FH Summit Japan 2026

Familial Hypercholesterolemia (FH) Summit Japan 2026

Satellite Symposium of the 58th Annual Meeting of the Japan Atherosclerosis Society

Join FH Summit Japan 2026 to learn the latest in familial hypercholesterolemia (FH) from leading experts worldwide

Register here

Program

Opening Remarks

9:55–10:00 am
Hayato Tada (Kanazawa University)
Chair, Familial Hypercholesterolemia Committee, Japan Atherosclerosis Society

Session 1: Young Investigator Session on FH Research

10:00 – 11:00 am
Chair: Hiroaki Okazaki (Teikyo University Hospital, Mizonokuchi)
Speaker:
Sex-Related Differences in Clinical, Demographics, and Outcome Characteristics in Japanese Patients with Heterozygous Familial Hypercholesterolaemia: Insight from the PROLIPID study
Yasuaki Takeji (Kanazawa University)

Clinical features and mortality in Korean individuals with HoFH-compatible LDL-C levels
Kyuho Kim (The Catholic University of Korea)

Discordance in Achilles Tendon Assessment between Radiography and Ultrasonography due to Torsion
Kenta Sakaguchi (Osaka Medical and Pharmaceutical University)

Developing a National Health Screening–Based System for Familial Hypercholesterolemia Detection in South Korea: Targeted NGS and Genetic Cascade Screening
Jung-Ho Yang (Chonnam National University)

Session 2: JAS–KSoLA Joint Symposium
Diagnosis and Management of Familial Hypercholesterolemia in East Asia

11:00 – 12:00 am
Chair: Daisaku Masuda (Sumitomo Mitsui Banking Corporation, Rinku General Medical Center)
Speaker:
Beyond the European Paradigm: Familial Hypercholesterolemia as a Cerebrovascular Risk Factor in Japan
Yorito Hattori (National Cerebral and Cardiovascular Center)

Coronary artery disease prediction in Korean patients with familial hypercholesterolemia
Sang-Hak Lee (Yonsei University)

Pregnancy and Childbirth in women with FH: Challenges and Insights from a Patient survey
Makiko Egawa (Institute of Science Tokyo)

Session 3: FH Academy (Luncheon Seminar)

12:10 – 1:00 pm
Chair: Kenta Mori (Toyooka Hospital)
Speaker:
FH Academy 2025: A Summary Report
Masatsune Ogura (Juntendo University)

From FH Academy to Practice: Institutional Implementation and Outcomes
Shigeyasu Tsuda (Kita-Harima Medical Center)

Sponsored by Amgen K.K.

Session 4: Familial Hypercholesterolemia and Lipoprotein(a)

1:10 – 2:10 pm
Chair: Masayuki Yoshida (Institute of Science Tokyo)
Speaker:
An Overview of FH and Lipoprotein(a): Double Hit by Two Important Risk Factors
Florian Kronenberg (Medical University of Innsbruck)

Lipoprotein(a) and FH: Findings from LEAP Study
Tomoaki Yamada (Institute of Science Tokyo)

Characterization of Lp（a） in Japanese FH Patients
Kota Murai (National Cerebral and Cardiovascular Center)

Session 5: Homozygous Familial Hypercholesterolemia

2:20 – 3:40 pm

Chair: Mariko Harada-Shiba (Osaka Medical and Pharmaceutical University)
Speaker:
An Initiative for the Early Diagnosis of Pediatric Familial Hypercholesterolemia Using School Health Screenings in Kagawa
Keiji Matsunaga (National Cerebral and Cardiovascular Center)

Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia (HoFH) in Japan 2026　～The Significance of the Focused Update of the Adult Familial Hypercholesterolemia Clinical Practice Guidelines～
Hayato Tada (Kanazawa University),

Atherosclerosis in HoFH: How can we better manage LDL-C and other risks?
Yu Kataoka (National Cerebral and Cardiovascular Center)

Panel Discussion

Sponsored by Ultragenyx Japan K.K.

Closing Remarks

3:40 – 3:45 pm
Mariko Harada-Shiba (Osaka Medical and Pharmaceutical University)
Former Chair, Familial Hypercholesterolemia Committee, Japan Atherosclerosis Society